Rheumatology

Phase III clinical trials analysed the efficaPhase III clinical trials analysed the efficacy of a novel antibody, guselkumab, for psoriatic arthritis with axial symptoms.

EXERCISE reduces the risk of cardiovascular disease in those with rheumatic disorders. Individuals with autoimmune rheumatic diseases (ARDs), such as rheumatoid arthritis and lupus, are more likely to develop atherosclerosis and are thereby at a higher risk of a heart attack and other cardiovascular disorders.

LUPUS could now be treated with a lower dose of steroids, lessening the side effects experienced by patients and improving their health long-term. The research was published by Eric Morand and the Rheumatology Group at Monash University, Melbourne, Australia, who aimed to gain insight into ways of tracking patient exposure to steroids.

COLCHICINE, an anti-inflammatory oral drug commonly used for the treatment of gout and rheumatic diseases, has reportedly been shown to significantly…

OSTEOPONTIN (OPN), a protein known to function as an immune system modulator and play a role in tissue regeneration, may be responsible for driving lung…

THE EUROPEAN League Against Rheumatism (EULAR) has collated and released its first consensus-based recommendations for prospective pregnancy registries…

CYTOKINE storm is the term given to immune responses triggered by escalated infections, such as in the coronavirus disease (COVID-19). Severe immune…

ADDICTIVE opioids are routinely taken by many people with arthritis to manage their pain. Kappa opioid receptor (KOR) agonists are known to be less…